Pharming Group (ENXTAM:PHARM) - Cotización, noticias y análisis

Resumen de acción PHARM

Pharming Group N.V., empresa biofarmacéutica, desarrolla y comercializa terapias de sustitución de proteínas y medicamentos de precisión para el tratamiento de enfermedades raras en Estados Unidos, Europa y a escala internacional. Saber más

Análisis fundamental de PHARM
Puntuación del snowflake
Valoración	6/6
Crecimiento futuro	4/6
Rendimiento pasado	0/6
Salud financiera	5/6
Dividendos	0/6

Recompensas

Cotiza un 91.2% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 73.16%

Cotiza a buen valor en comparación con empresas similares e industria

Los analistas coinciden en que el precio de las acciones subirá un 151.4%

Análisis de riesgos

Volatilidad del precio de la acción en los últimos 3 meses

Competidores de Pharming Group N.V.

Galapagos

ENXTAM:GLPG

€1.7b

Medy-Tox

KOSDAQ:A086900

₩867.0b

Beijing Kawin Technology Share-Holding

SHSE:688687

CN¥4.3b

Basilea Pharmaceutica

SWX:BSLN

CHF 500.6m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Pharming Group
Precios históricos de las acciones
Precio actual de la acción	€0.72
Máximo en las últimas 52 semanas	€1.22
Mínimo de 52 semanas	€0.65
Beta	0.81
1Cambio en 1 mes	-10.95%
Variación en 3 meses	1.92%
Cambio de 1 año	-32.07%
3Variación en 3 años	0.084%
Variación en 5 años	-49.68%
Variación desde la OPV	-99.24%

Noticias y actualizaciones recientes

Recent updates

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Nov 11

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 23

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Jun 20

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Mar 16

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 17

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Dec 08

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Aug 05

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

Mar 21

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Mar 19

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Feb 20

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Oct 29

Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Jun 03

Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

May 12

Rentabilidad de los accionistas

	PHARM	NL Biotechs	Mercado NL
7D	0.4%	3.8%	0.9%
1Y	-32.1%	6.0%	7.6%

Rentabilidad vs. Industria: Los resultados de PHARM fueron inferiores a los de la industria Dutch Biotechs, que obtuvo un rendimiento del 6% el año pasado.

Rentabilidad vs. Mercado: PHARM obtuvo unos resultados inferiores a los del mercado Dutch, que fueron del 7.6% el año pasado.

Volatilidad de los precios

Is PHARM's price volatile compared to industry and market?
PHARM volatility
PHARM Average Weekly Movement	6.9%
Biotechs Industry Average Movement	7.5%
Market Average Movement	4.0%
10% most volatile stocks in NL Market	7.2%
10% least volatile stocks in NL Market	2.2%

Precio estable de las acciones: El precio de las acciones de PHARM ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de PHARM(7%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de Dutch.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1988	382	Simon de Vries	www.pharming.com

Pharming Group N.V., empresa biofarmacéutica, desarrolla y comercializa terapias de sustitución proteica y medicamentos de precisión para el tratamiento de enfermedades raras en Estados Unidos, Europa y a escala internacional. La empresa ofrece RUCONEST, un inhibidor recombinante de la C1 esterasa para el tratamiento de ataques agudos en pacientes adultos y adolescentes con angioedema hereditario agudo (AEH); y Joenja (leniolisib), un inhibidor oral de PI3K? de molécula pequeña para el tratamiento del síndrome de fosfoinositido 3-cinasa delta activada.

Resumen de fundamentos de Pharming Group N.V.

¿Cómo se comparan los beneficios e ingresos de Pharming Group con su capitalización de mercado?
Estadísticas fundamentales de PHARM
Capitalización bursátil	€485.70m
Beneficios(TTM)	-€17.12m
Ingresos (TTM)	€274.40m

1.8x

Ratio precio-ventas (PS)

-28.4x

Ratio precio-beneficio (PE)

¿Está PHARM sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de PHARM
Ingresos	US$285.75m
Coste de los ingresos	US$30.30m
Beneficio bruto	US$255.44m
Otros gastos	US$273.26m
Beneficios	-US$17.82m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.026
Margen bruto	89.39%
Margen de beneficio neto	-6.24%
Ratio deuda/patrimonio	42.3%

¿Cómo se ha desempeñado PHARM a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción PHARM

Recompensas

Análisis de riesgos

Competidores de Pharming Group N.V.

ENXTAM:GLPG

€1.7b

KOSDAQ:A086900

₩867.0b

SHSE:688687

CN¥4.3b

SWX:BSLN

CHF 500.6m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Consensus estimates of losses per share improve by 14%

Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023)

Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation

New minor risk - Share price stability

Price target decreased by 7.8% to €1.78

New minor risk - Share price stability

Recent updates

Consensus estimates of losses per share improve by 14%

Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023)

Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation

New minor risk - Share price stability

Price target decreased by 7.8% to €1.78

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.002 loss per share (vs US$0.002 profit in 2Q 2023)

Insufficient new directors

Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union

Pharming Group N.V. Provides Revenue Guidance for 2024

First quarter 2024 earnings released: US$0.019 loss per share (vs US$0.019 loss in 1Q 2023)

Pharming Group N.V. announced that it expects to receive €100 million in funding

Price target increased by 11% to €2.00

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Consensus estimates of losses per share improve by 31%

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Consensus EPS estimates upgraded to US$0.014 loss, revenue downgraded

Consensus estimates of losses per share improve by 34%

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 140%

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022)

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Now 20% undervalued

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Investor sentiment improves as stock rises 15%

Price target increased by 8.9% to €1.83

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Now 20% undervalued

Now 20% undervalued

Investor sentiment improved over the past week

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

High number of new directors

Investor sentiment improved over the past week

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Third quarter 2022 earnings: EPS exceeds analyst expectations

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Price target increased to €13.52

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations